Anavex Life Sciences Corp (AVXL)

[tredenwater2]

The EMA would then decide on what the path should be for the lesser performing group(s), once the data had been collected over an adequate period of time.

What a wonderful problem to have for the EMA.. Approving a drug that is easy to administer, has a great safety record, and highly efficacious for 70% of its users.

The mabs dont stand a chance upon our approval. That is the real battle behind the scenes, who is going to approve us putting their neck out there and risk losing multi millions of dollars of scientific “funding”.